Tyra Biosciences' Exciting Announcement at ENDO 2025
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company, has made a significant stride in the field of precision medicine. They announced a highly anticipated late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025). This event is set to occur shortly, and it underscores Tyra's commitment to advancing treatments that target critical opportunities in Fibroblast Growth Factor Receptor (FGFR) biology.
Details of the Poster Presentation
The poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," promises to shed light on groundbreaking research. The presenting author, Dr. Jacqueline H. Starrett from Tyra Biosciences, will delve into the innovative findings that illustrate the positive impact of TYRA-300 on bone growth, a vital aspect of treating related conditions.
Presentation Information
Here are the critical details regarding the presentation at ENDO 2025:
- Abstract: SUN-730
- Date/Time: July 13, with the presentation scheduled from 12:00 PM to 1:30 PM
- Location: ENDOExpo, Poster Area
- Session: P70 - BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders
About TYRA-300
At the heart of Tyra Biosciences’ innovation is TYRA-300, an investigational drug developed through their proprietary SNÅP platform, specifically designed as an oral, FGFR3-selective inhibitor. This drug is at the forefront of the company's pipeline and has exhibited promising interim clinical proof-of-concept results in metastatic urothelial cancer (mUC). The comprehensive development of TYRA-300 includes three Phase 2 clinical trials: SURF302 targeting intermediate risk non-muscle invasive bladder cancer (IR NMIBC), BEACH301 for pediatric achondroplasia, and SURF301 aimed at mUC. Each trial represents a step towards enhancing treatment options for various patient populations.
Carrying Forward the Promise of Precision Medicine
Tyra Biosciences continuously seeks to provide advanced healthcare solutions that improve patients' lives. TYRA-300 is positioned to be a potential first-in-class selective FGFR3 inhibitor that avoids the common toxicities associated with the inhibition of other FGFR subtypes, making it a groundbreaking therapeutic candidate. Such innovations exemplify the company's dedication to addressing significant medical needs.
Further Information About Tyra Biosciences
Tyra Biosciences specializes in developing cutting-edge precision medicines that leverage advancements in FGFR biology. The company’s innovative SNÅP platform plays a crucial role, allowing rapid drug design through iterative molecular snapshots aimed at overcoming genetic resistance to existing therapies. Tyra’s pipeline, featuring TYRA-300 among others, includes targeted programs that stand to revolutionize treatment protocols in oncology and genetically defined conditions.
In addition to TYRA-300, the company is also progressing with other investigational drugs, including TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral FGFR4/3-biased inhibitor for cancers driven by FGF19 and FGFR4. Each of these development programs reflects Tyra's commitment to advancing the science of biomedicine in the ongoing fight against cancer and other serious diseases.
Frequently Asked Questions
What is TYRA-300?
TYRA-300 is an investigational oral FGFR3-selective inhibitor developed by Tyra Biosciences for treating various conditions including cancer.
When is the poster presentation scheduled?
The poster presentation will take place on July 13, during the ENDO 2025 conference.
Who will present the findings on TYRA-300?
Dr. Jacqueline H. Starrett will present the findings related to TYRA-300.
What are the ongoing trials for TYRA-300?
TYRA-300 is currently involved in three Phase 2 clinical trials focusing on bladder cancer, pediatric conditions, and metastatic urothelial cancer.
How does Tyra Biosciences contribute to precision medicine?
Tyra Biosciences utilizes its innovative SNÅP platform to design precise drugs targeting genetic alterations, enhancing the efficacy of treatments.
